Back to Agenda
Precision Medicine into Action: The Case of a Histology Independent Label - What Implications for Value Assessment?
Session Chair(s)
Sophie Cooper
Scientific Adviser
National Institute for Health and Care Excellence (NICE), United Kingdom
A histology-independent label (encompassing all tumours with a common biomarker, regardless of tumour type) will cover an extremely heterogeneous population with varied comparators and prognoses, and likely be based on evidence from non comparative basket trials, with little or no data on survival outcomes. Representatives from health technology assessment (HTA) bodies, industry and patient organisations will discuss the challenges this poses for the value assessment of these drugs, and explore possible solutions to facilitate timely access to potentially innovative treatments for patients with no alternative options.
Speaker(s)
Panel Discussion
Linda Landells, PhD
National Institute for Health and Care Excellence (NICE), United Kingdom
Associate Director Technology Appraisals (Cancer Drugs Fund)
Panel Discussion
Iain Leslie
Roche Products Ltd, United Kingdom
Health Outcomes Manager
Panel Discussion
Bettina Ryll
MPNE, Vision Zero Cancer, Sweden
Member of the First EU Cancer Mission Board
Panel Discussion
Anja Schiel, PhD
Norwegian Medicines Agency (NoMA), Norway
Special Advisor, Lead Methodologist; Leader international HTA (iHTA) NoMA
Panel Discussion
Stephen Palmer
University of York, United Kingdom
Professor
Have an account?